Next Article in Journal
The Effects of Pre-Existing Antibodies on Live-Attenuated Viral Vaccines
Next Article in Special Issue
Special Issue “Virus-Like Particle Vaccines”
Previous Article in Journal
TRiC/CCT Complex, a Binding Partner of NS1 Protein, Supports the Replication of Zika Virus in Both Mammalians and Mosquitoes
Previous Article in Special Issue
Virus-Like Particles as an Immunogenic Platform for Cancer Vaccines
Review

Influenza Virus Like Particles (VLPs): Opportunities for H7N9 Vaccine Development

Medigen, Inc., 8420 Gas House Pike, Suite S, Frederick, MD 21701, USA
*
Author to whom correspondence should be addressed.
Viruses 2020, 12(5), 518; https://doi.org/10.3390/v12050518
Received: 2 April 2020 / Revised: 21 April 2020 / Accepted: 27 April 2020 / Published: 8 May 2020
(This article belongs to the Special Issue Virus-Like Particle Vaccines)
In the midst of the ongoing COVID-19 coronavirus pandemic, influenza virus remains a major threat to public health due to its potential to cause epidemics and pandemics with significant human mortality. Cases of H7N9 human infections emerged in eastern China in 2013 and immediately raised pandemic concerns as historically, pandemics were caused by the introduction of new subtypes into immunologically naïve human populations. Highly pathogenic H7N9 cases with severe disease were reported recently, indicating the continuing public health threat and the need for a prophylactic vaccine. Here we review the development of recombinant influenza virus-like particles (VLPs) as vaccines against H7N9 virus. Several approaches to vaccine development are reviewed including the expression of VLPs in mammalian, plant and insect cell expression systems. Although considerable progress has been achieved, including demonstration of safety and immunogenicity of H7N9 VLPs in the human clinical trials, the remaining challenges need to be addressed. These challenges include improvements to the manufacturing processes, as well as enhancements to immunogenicity in order to elicit protective immunity to multiple variants and subtypes of influenza virus. View Full-Text
Keywords: H7N9; pandemic influenza A; avian flu; IAV; VLP vaccine H7N9; pandemic influenza A; avian flu; IAV; VLP vaccine
Show Figures

Figure 1

MDPI and ACS Style

Pushko, P.; Tretyakova, I. Influenza Virus Like Particles (VLPs): Opportunities for H7N9 Vaccine Development. Viruses 2020, 12, 518. https://0-doi-org.brum.beds.ac.uk/10.3390/v12050518

AMA Style

Pushko P, Tretyakova I. Influenza Virus Like Particles (VLPs): Opportunities for H7N9 Vaccine Development. Viruses. 2020; 12(5):518. https://0-doi-org.brum.beds.ac.uk/10.3390/v12050518

Chicago/Turabian Style

Pushko, Peter, and Irina Tretyakova. 2020. "Influenza Virus Like Particles (VLPs): Opportunities for H7N9 Vaccine Development" Viruses 12, no. 5: 518. https://0-doi-org.brum.beds.ac.uk/10.3390/v12050518

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop